Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 vs investigator’s choice chemotherapy in HER2-expressing platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
CTR20250550Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab rezetecan in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Hengrui Therapeutics. Started Mar 2025; status: active.
02
Drugs
trastuzumab rezetecan
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20250550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250550.